Controversies in Hepatocellular Carcinoma

Section 1 - Risk Assessment and Chemoprevention.- Controversy 1 - Should All Patients with Hepatitis B Virus Undergo Hepatocellular Carcinoma Surveillance?.- Controversy 2 - Should Hepatocellular Carcinoma Surveillance Be Restricted to Those with Cirrhosis Among Patients With Hepatitis C?.- Controversy 3 - Should Hepatocellular Carcinoma Surveillance Be Performed in Patients with Noncirrhotic Nonalcoholic Steatohepatitis?.- Controversy 4 -Can Risk Stratification Models Be Used to Identify Patients without Cirrhosis who Might Benefit From Hepatocellular Carcinoma Surveillance?.- Controversy 5 - Should Hepatocellular Carcinoma Surveillance Be Performed Only for Patients with Decompensated Cirrhosis if They Are Listed for Liver Transplantation?.- Controversy 6 - Should Statins and Aspirin Be Used for Hepatocellular Carcinoma Chemoprevention in Patients with Cirrhosis?.- Section 2 - Liver Cancer Surveillance.- Controversy 7 - Should A Randomized Controlled Trial of Hepatocellular Carcinoma in Patients with Cirrhosis Be Performed?.- Controversy 8 - Should Contrast-Enhanced Computed Tomography and/or Magnetic Resonance Imaging Play a Routine Role in Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis?.- Controversy 9 - Should Biomarkers, Such as Alpha Fetoprotein, Play a Routine Role in Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis?.- Controversy 10 - Should Patients with Hepatitis C Virus Cirrhosis Undergo Hepatocellular Carcinoma Surveillance Indefinitely?.- Controversy 11 - Should Patients with Hepatitis C Virus Cirrhosis Undergo Hepatocellular Carcinoma Surveillance Indefinitely?.- Section 3 - Diagnosis.- Controversy 12 - Should All Liver Lesions in Patients with Cirrhosis Be Characterized and Reported Using Liver Imaging Reporting and Data System Criteria?.- Controversy 13 - Can Imaging Findings of Arterial Enhancement and Washout Still Represent a Benign Liver Lesion?.- Controversy 14 - Should Diagnostic Liver Biopsy Be Performed in Patients with Cirrhosis who Have Characteristic Imaging Features of Hepatocellular Carcinoma?.- Controversy 15 - Is Contrast-Enhanced Ultrasound Sufficiently Accurate to Be Used for Noninvasive Diagnosis of Hepatocellular Carcinoma?.- Section 4 - Prognosis.- Controversy 16 - Should Barcelona Clinic Liver Cancer Staging Be Used as the Preferred Staging System for Hepatocellular Carcinoma?.- Section 5 - TreatmentControversy 17 - Should Resection Be the Preferred Therapeutic Option for Patients Within the Milan Criteria and Compensated Cirrhosis Without Portal Hypertension?.- Controversy 18 - Should Liver Transplantation Be the Preferred Therapeutic Option in Patients with Compensated Cirrhosis and Portal Hypertension?.- Controversy 19 - Should Radiation-Based Therapy Be Considered in All Patients with Hepatocellular Carcinoma?.- Controversy 20 - Should Transarterial Radioembolization be the First-Line Therapy Compared to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma?.- Controversy 21 - Should All Patients Listed for Liver Transplantation Receive Bridging Therapy Before Transplant?.- Controversy 22 - Should Transplant Criteria Be Broadened Beyond United Network for Organ Sharing (UNOS) Downstaging Protocol to Include Larger Tumors?.- Controversy 23 - Should All Tyrosine Kinase Inhibitors Be Considered Equal for First-Line Hepatocellular Carcinoma Treatment?.- Controversy 24 - Should All Patients Be Considered for Locoregional Therapy Before Systemic Therapy?.- Controversy 25 - Should Direct-Acting Antivirals Be Given to Patients with Hepatocellular Carcinoma?.- Controversy 26 - Should Locoregional Therapy Be Given in Combination with Systemic Therapy?.- Controversy 27 - Should Patients with Decompensated Cirrhosis Receive Systemic Therapy?.- Controversy 28 - Would Effectively Downstaging Hepatocellular Carcinoma Allow All Patients to Be Considered for Liver Transplantation?.- Controversy 29 - Should Surgery Be Considered for Hepatocellular Carcinoma if Unable to Be Performed at Presentation?.- Controversy 30- Should Rapamune (Sirolimus)-Based Immunomodulation Be Given Post Transplant for Those Transplanted for or Found to Have Incidental Hepatocellular.- Controversy 31- Should Systemic Therapy Be Offered to all Patients Post Transplant for Those Transplanted for or Found to Have Incidental Hepatocellular Carcinoma?.- Controversy 32 - Should Post-Liver Transplantation Surveillance for Hepatocellular Carcinoma (HCC) Stop if There Is no HCC Recurrence After 5 Years?.